A Comprehensive Technical White Paper on Chemistry, Fermentation Manufacturing, CMC Development, DMF Support, Quality Standards, and Industrial Production Economics
Executive Summary
Streptomycin Sulfate is a globally recognized aminoglycoside antibiotic produced through advanced microbial fermentation technology. Since its introduction into clinical medicine, it has played a critical role in the treatment of tuberculosis, brucellosis, tularemia, plague, and a variety of veterinary bacterial infections. Despite the emergence of newer antimicrobial agents, streptomycin sulfate continues to maintain strategic importance in pharmaceutical manufacturing, veterinary healthcare, agricultural disease management, and microbiological research.
As a fermentation-derived Active Pharmaceutical Ingredient (API), streptomycin sulfate represents one of the earliest successful examples of industrial biotechnology. Modern production integrates microbial strain improvement, precision fermentation, downstream purification, crystallization engineering, and pharmaceutical-grade quality assurance systems.
This white paper provides a comprehensive review of the chemistry, biosynthesis, manufacturing process, process engineering considerations, pharmacopoeial standards, market outlook, and future development trends associated with Streptomycin Sulfate (CAS 3810-74-0).
1. Product Overview
Chemical Identity
| Parameter | Specification |
| Product Name | Streptomycin Sulfate |
| CAS Number | 3810-74-0 |
| Molecular Formula | (C21H39N7O12)2·3H2SO4 |
| Molecular Weight | Approx. 1457.4 |
| Antibiotic Class | Aminoglycoside |
| Origin | Fermentation Derived |
| Appearance | White to Off-White Powder |
| Solubility | Freely Soluble in Water |
| Pharmacopoeial Status | USP / EP / JP |
Streptomycin sulfate is produced through controlled fermentation of selected strains of Streptomyces griseus, followed by extensive purification and conversion into a pharmaceutically acceptable sulfate salt.
The sulfate form offers:
- Improved storage stability
- Enhanced aqueous solubility
- Excellent compatibility with injectable formulations
- Superior handling characteristics during pharmaceutical processing
2. Molecular Structure and Physicochemical Characteristics
The molecular architecture of streptomycin consists of three major structural domains:
Streptidine
A guanidino-containing cyclitol ring responsible for ionic interactions with bacterial ribosomes.
Streptose
An unusual sugar moiety contributing to molecular recognition.
N-Methyl-L-Glucosamine
Participates in hydrogen bonding interactions with ribosomal RNA.
The sulfate counterions stabilize the molecule and improve physicochemical performance during formulation and storage.
Key Physicochemical Properties
Solubility
Highly water-soluble (>500 mg/mL under appropriate conditions).
Hygroscopicity
Moderately hygroscopic; controlled humidity storage is recommended.
Thermal Behavior
Stable under standard storage conditions but susceptible to degradation under prolonged elevated temperatures.
pH Stability
Maximum stability is generally observed between pH 4.5 and 7.0.
Optical Activity
Multiple chiral centers require preservation of stereochemical integrity throughout manufacturing.
3. Mechanism of Action
Streptomycin sulfate exerts bactericidal activity through inhibition of bacterial protein synthesis.
Primary Target
30S Ribosomal Subunit
Following cellular uptake, streptomycin binds to bacterial ribosomal RNA and causes:
- Misreading of mRNA
- Premature termination of translation
- Production of defective proteins
- Membrane dysfunction
- Cell death
The irreversible nature of ribosomal binding contributes significantly to its bactericidal efficacy.
4. Biosynthetic Pathway and Fermentation Metabolism
Biological Origin
Industrial streptomycin is produced by fermentation of selected Streptomyces griseus strains.
Unlike chemically synthesized antibiotics, streptomycin is generated through highly regulated secondary metabolic pathways.
4.1 Biosynthetic Precursors
The biosynthesis begins with primary metabolic intermediates derived from:
Carbohydrate Metabolism
- Glucose
- Starch hydrolysates
- Dextrins
These carbon sources enter glycolysis and the pentose phosphate pathway.
Nitrogen Metabolism
Nitrogen sources contribute amino groups required for:
- Streptidine synthesis
- Aminosugar biosynthesis
- Guanidino group formation
4.2 Streptomycin Biosynthetic Pathway
The simplified pathway can be represented as:
Glucose
↓
Glucose-6-Phosphate
↓
Pentose Phosphate Pathway
↓
Sugar Nucleotide Precursors
↓
Streptidine Formation
+
Streptose Formation
+
N-Methyl-L-Glucosamine Formation
↓
Intermediate Condensation
↓
Dihydrostreptomycin Precursors
↓
Streptomycin
↓
Fermentation Broth
More than twenty enzymes participate in this biosynthetic network.
Key enzyme categories include:
- Glycosyltransferases
- Aminotransferases
- Oxidoreductases
- Methyltransferases
4.3 Metabolic Engineering Opportunities
Modern strain development focuses on:
Carbon Flux Optimization
Redirecting carbon utilization toward antibiotic biosynthesis.
Nitrogen Utilization Enhancement
Improving precursor availability.
Regulatory Gene Manipulation
Activation of secondary metabolite pathways.
Byproduct Reduction
Minimizing formation of undesirable metabolites.
Advanced genomic engineering has enabled substantial yield improvements compared with original industrial strains.
5. Industrial Manufacturing Process
Process Flow Diagram (PFD)
The industrial manufacturing process can be represented as:
Raw Materials
↓
Medium Preparation
↓
Sterilization
↓
Seed Culture Development
↓
Production Fermentation
↓
Broth Filtration
↓
Cell Removal
↓
Primary Purification
↓
Ion Exchange Recovery
↓
Concentration
↓
Sulfate Salt Conversion
↓
Crystallization
↓
Solid-Liquid Separation
↓
Drying
↓
Milling and Blending
↓
Quality Control Testing
↓
Packaging
↓
Finished API
6. Fermentation Process Engineering
Seed Train Development
Industrial production typically employs a multi-stage inoculum expansion strategy:
Stage 1
Working Cell Bank
Stage 2
Shake Flask Cultivation
Stage 3
Seed Fermenter
Stage 4
Production Fermenter
This approach ensures culture vitality and minimizes genetic drift.
Production Fermentation
Typical Operating Parameters
| Parameter | Range |
| Temperature | 27–30°C |
| pH | 6.8–7.3 |
| Dissolved Oxygen | >20% |
| Aeration | 0.5–1.5 VVM |
| Fermentation Time | 120–240 Hours |
Because streptomycin production is highly oxygen-dependent, oxygen transfer coefficient (kLa) becomes a critical process parameter.
Fermentation Challenges
Key engineering challenges include:
Oxygen Limitation
May reduce antibiotic productivity.
Foam Formation
Requires controlled antifoam addition.
Nutrient Imbalance
Can trigger unwanted byproduct generation.
Contamination Control
Requires strict aseptic operation.
Modern facilities employ advanced Process Analytical Technology (PAT) systems for real-time monitoring.
7. Downstream Processing Technology
Downstream processing typically contributes 40–60% of overall manufacturing cost.
Broth Clarification
Techniques include:
- Rotary vacuum filtration
- Disc-stack centrifugation
- Crossflow microfiltration
Objective:
Removal of microbial biomass while maximizing product recovery.
Ion Exchange Purification
Because streptomycin contains multiple protonatable amino groups, ion exchange chromatography provides efficient separation.
Advantages:
- High selectivity
- Scalable operation
- Reduced impurity burden
Concentration
Methods include:
- Vacuum evaporation
- Nanofiltration
- Reverse osmosis
Process temperatures are carefully controlled to prevent degradation.
Sulfation Step
Purified streptomycin base is reacted with pharmaceutical-grade sulfuric acid under controlled conditions.
Critical parameters:
- pH
- Temperature
- Reaction time
- Sulfate stoichiometry
The resulting streptomycin sulfate exhibits superior pharmaceutical stability.
Crystallization Engineering
Crystallization directly affects:
- Particle size distribution
- Bulk density
- Flowability
- Filtration behavior
Seeded crystallization is commonly used to ensure batch-to-batch consistency.
8. Quality Control and Regulatory Compliance
Pharmaceutical-grade streptomycin sulfate must comply with international pharmacopoeial standards.
9. Comparative Pharmacopoeial Standards
USP vs EP vs JP Comparison
| Parameter | USP | EP | JP |
| Identification | Required | Required | Required |
| Potency Assay | Required | Required | Required |
| Sulfate Content | Required | Required | Required |
| pH | Specified | Specified | Specified |
| Water Content | Controlled | Controlled | Controlled |
| Related Substances | Controlled | Controlled | Controlled |
| Microbial Limits | Required | Required | Required |
| Endotoxin Testing | Product Dependent | Product Dependent | Product Dependent |
USP Requirements
The United States Pharmacopeia focuses heavily on:
- Potency determination
- Related substances
- Microbiological quality
- Identity confirmation
Modern methods increasingly rely on HPLC-based analysis.
European Pharmacopoeia (EP)
EP requirements emphasize:
- Comprehensive impurity profiling
- Sulfate content verification
- Water determination
- Biological potency
Particular attention is given to process-derived impurities.
Japanese Pharmacopoeia (JP)
JP standards generally align with USP and EP while incorporating region-specific analytical procedures.
Focus areas include:
- Identity testing
- Potency verification
- Purity assessment
- Manufacturing consistency
10. Quality-by-Design (QbD) Considerations
Modern facilities increasingly implement ICH Q8 principles.
Critical Quality Attributes (CQAs)
Examples include:
- Potency
- Impurity profile
- Water content
- Sulfate ratio
- Particle size distribution
Critical Process Parameters (CPPs)
Examples include:
- Fermentation pH
- Dissolved oxygen
- Elution conditions
- Crystallization temperature
Control of CPPs ensures consistent product quality.
11. Environmental and Sustainability Considerations
Modern manufacturers face increasing environmental expectations.
Major focus areas include:
Water Consumption Reduction
Implementation of recycling systems.
Energy Optimization
Use of high-efficiency aeration technologies.
Wastewater Treatment
Removal of residual antibiotics before discharge.
Carbon Footprint Reduction
Integration of renewable energy and process optimization.
12. Global Market Analysis
Market Overview
Although streptomycin is a mature antibiotic, global demand remains stable due to:
- Tuberculosis treatment programs
- Veterinary healthcare demand
- Laboratory applications
- Agricultural disease control
The global market is generally characterized as a specialty antibiotic segment within the broader aminoglycoside market.
Market Segmentation
By Application
Human Pharmaceuticals
Approximately 40–50%
Veterinary Pharmaceuticals
Approximately 30–40%
Agriculture
Approximately 5–15%
Research and Diagnostics
Approximately 5–10%
Regional Demand Distribution
Asia-Pacific
Largest production and consumption region.
Growth drivers include:
- Expanding pharmaceutical manufacturing
- Veterinary sector growth
- Cost-competitive fermentation infrastructure
Europe
Demand supported by:
- Pharmaceutical applications
- Veterinary medicine
- Research institutions
North America
Demand remains stable due to:
- Research use
- Specialty pharmaceutical formulations
- Veterinary applications
Latin America and Africa
Growing consumption associated with infectious disease management and agricultural development.
13. Future Industry Trends
The future of streptomycin sulfate manufacturing will likely be influenced by several technological trends.
Precision Fermentation
AI-assisted fermentation optimization is expected to improve productivity and consistency.
Synthetic Biology
Genome-scale engineering may significantly increase biosynthetic efficiency.
Continuous Bioprocessing
Continuous fermentation and purification technologies could reduce production costs.
Green Manufacturing
Sustainability metrics will become increasingly important for regulatory approval and customer acceptance.
Advanced Analytics
Integration of:
- Digital twins
- Machine learning
- Predictive process control
will enable next-generation manufacturing excellence.
Conclusion
Streptomycin Sulfate (CAS 3810-74-0) remains one of the most historically significant and commercially relevant fermentation-derived antibiotics. Its production exemplifies the successful integration of industrial microbiology, biochemical engineering, downstream purification, and pharmaceutical quality systems.
Modern manufacturing processes combine advanced strain engineering, precision fermentation, sophisticated purification technologies, and rigorous regulatory compliance to deliver high-quality pharmaceutical-grade material. As the global pharmaceutical industry continues to evolve toward sustainability, digitalization, and process intensification, streptomycin sulfate manufacturing is expected to benefit from emerging innovations in synthetic biology, continuous bioprocessing, and intelligent manufacturing systems.
Despite being a mature product, Streptomycin Sulfate continues to occupy an important position in human health, veterinary medicine, agriculture, and scientific research, ensuring its long-term relevance in the global life sciences industry.
14. CMC (Chemistry, Manufacturing, and Controls) Technical Section
The CMC section of Streptomycin Sulfate provides a comprehensive overview of all aspects related to chemistry, manufacturing, and quality controls, aligned with FDA and EMA requirements. It encompasses raw material sourcing, microbial fermentation, purification strategies, analytical methods, and final product specifications.
14.1 Chemistry
14.1.1 Molecular Structure and Composition
Streptomycin Sulfate is an aminoglycoside composed of:
- Streptidine nucleus
- Streptose sugar
- N-methyl-L-glucosamine
The sulfate form contains three sulfate counterions per two molecules of streptomycin. The molecule contains multiple amino and hydroxyl groups, contributing to high polarity and water solubility.
14.1.2 Physicochemical Properties
| Property | Value |
| Molecular weight | ~1457.4 g/mol |
| Water solubility | >500 mg/mL |
| Melting point | Decomposes above 220°C |
| pH (1% aqueous solution) | 4.5–7.0 |
| Optical rotation | +50° to +55° (specific rotation) |
| Hygroscopicity | Moderate; controlled humidity recommended |
The stereochemistry of all chiral centers is critical for biological activity. Therefore, all processes maintain stereochemical integrity, and analytical methods ensure chiral purity.
14.2 Manufacturing
14.2.1 Raw Materials
Critical raw materials include:
- Carbon sources: Glucose, starch hydrolysates, dextrin
- Nitrogen sources: Soybean meal, yeast extract, corn steep liquor
- Minerals: MgSO₄, CaCO₃, KH₂PO₄, trace elements
- Sulfuric acid: Pharmaceutical grade for salt formation
All raw materials are subject to quality verification, including identity, purity, microbial load, and heavy metals.
14.2.2 Fermentation
- Strain: Streptomyces griseus
- Seed train: multi-stage (slant → shake flask → seed fermenter → production fermenter)
- Production fermenter conditions: temperature 27–30°C, pH 6.8–7.3, dissolved oxygen >20%, aeration 0.5–1.5 VVM
- Fermentation time: 5–10 days
- Monitoring: biomass, glucose consumption, pH, dissolved oxygen, product concentration
Advanced PAT systems allow real-time monitoring of fermentation parameters, ensuring consistent quality and high yield.
14.2.3 Downstream Purification
Key operations:
- Broth Clarification: Rotary vacuum filtration or disc-stack centrifugation to remove microbial cells.
- Adsorption and Ion Exchange: Cation exchange resins selectively adsorb streptomycin.
- Elution and Concentration: Streptomycin is eluted and concentrated under controlled temperature.
- Sulfate Salt Formation: Reaction with pharmaceutical-grade H₂SO₄ to form streptomycin sulfate.
- Crystallization: Seeded crystallization ensures particle size uniformity.
- Drying and Milling: Vacuum or fluidized bed drying to target moisture content (<2%) and final powder particle size.
14.2.4 Process Controls and Quality Assurance
Critical Process Parameters (CPPs):
- pH and temperature during fermentation
- Dissolved oxygen
- Antifoam concentration
- Elution and crystallization temperatures
- Sulfation stoichiometry
Critical Quality Attributes (CQAs):
- Potency (bioassay or HPLC)
- Sulfate content
- Water content
- Impurity profile
- Microbial limits
- Particle size and flowability
Quality by Design (QbD) principles guide process validation, ensuring reproducibility, robustness, and regulatory compliance.
14.3 Analytical Methods
- HPLC: Quantitative determination of active ingredient
- LC-MS: Impurity profiling
- UV/Vis spectroscopy: Identity confirmation
- Titration: Sulfate content
- Moisture content: Karl Fischer method
- Microbial limit tests: Total aerobic count, yeast/mold, pathogens
- Optical rotation: Stereochemistry verification
All analytical methods are validated according to ICH Q2(R1) guidelines.
15. DMF Supporting Information Overview
A Drug Master File (DMF) provides regulators with confidential detailed information on the manufacturing process, analytical methods, and controls without disclosing proprietary details to the client. For Streptomycin Sulfate, the DMF contains:
15.1 Manufacturing Process Description
- Strain information (including identification and authentication methods)
- Seed train preparation and quality control
- Production fermentation conditions
- Downstream purification steps
- Sulfation process
- Crystallization, drying, and milling
- Packaging, labeling, and storage
Each step includes CPPs, in-process controls, and batch records.
15.2 Control of Materials
- Identity and quality testing for all raw materials
- Supplier qualification
- Traceability and documentation
- Acceptance criteria for each batch
15.3 Analytical Procedures
- Full description of all methods used for:
- Identity
- Assay
- Impurity detection
- Water content
- Sulfate content
- Microbial testing
- Endotoxin detection (if injectable API)
- Validation data including accuracy, precision, linearity, robustness
15.4 Stability Data
- Long-term stability (25°C/60% RH)
- Accelerated stability (40°C/75% RH)
- Light stability
- Moisture uptake studies
- Shelf-life assignment and storage conditions
The DMF also includes a risk assessment of degradation products and their potential impact on safety.
15.5 Regulatory Compliance
- Alignment with USP, EP, JP pharmacopoeial standards
- GMP compliance for manufacturing
- Data sufficient to support regulatory filings in multiple regions
- Confidential information kept separate from client submissions
16. Industrial Production Cost Analysis & Yield Optimization
16.1 Overview
Streptomycin sulfate production is capital and labor intensive. Cost drivers include fermentation media, energy consumption, labor, utilities, downstream purification, and waste treatment. Optimizing yield reduces production costs per kilogram.
16.2 Yield Analysis
16.2.1 Fermentation Yield
- Typical streptomycin concentration: 1.0–3.5 g/L
- Biomass: 10–15 g/L
- Yield optimization via:
- Strain improvement
- Controlled feeding of carbon and nitrogen
- Dissolved oxygen optimization
- pH stabilization
16.2.2 Recovery and Purification Yield
- Clarification: 95–98%
- Ion exchange recovery: 85–90%
- Sulfation reaction: 98%
- Crystallization and drying: 90–95%
- Overall yield: ~70–80% from fermentation broth to final API
16.3 Unit Cost Estimation
Cost elements:
- Raw materials: ~35–40%
- Energy (fermentation aeration, agitation, drying): ~20–25%
- Labor and quality control: ~15–20%
- Downstream purification consumables: ~15%
- Waste treatment and environmental compliance: ~5–10%
Optimizing process parameters and scaling to 10–20 ton annual capacity can significantly reduce per-kilogram cost.
16.4 Scale-Up Considerations
- Oxygen transfer limitations: addressed with higher-efficiency impellers
- Heat removal: critical for long fermentation cycles
- Antifoam compatibility with downstream purification
- Crystallizer design: ensures uniform particle size distribution
- Drying: moisture control to <2% ensures stability
16.5 Economic Implications of Process Improvements
- Increasing fermentation titer from 2 g/L to 3 g/L reduces raw material and energy cost per kg by ~30%
- Improving ion exchange efficiency from 85% to 90% improves overall yield by ~5%
- Integrated downstream processes can reduce labor and handling time by 15–20%
16.6 Sustainability and Cost Efficiency
- Wastewater recycling: reduces water and treatment costs
- Energy-efficient aeration and agitation: lowers electricity consumption
- Recovery of by-products: can provide secondary revenue streams
- Continuous monitoring: minimizes batch failure and improves consistency
17. Conclusion
The integration of advanced fermentation, downstream purification, and process control technologies enables the efficient and reliable production of high-quality Streptomycin Sulfate suitable for global pharmaceutical, veterinary, research, and agricultural applications. As one of the earliest industrial biotechnology products to achieve worldwide commercial success, streptomycin sulfate continues to serve as an excellent example of how microbiology, biochemical engineering, pharmaceutical science, and regulatory compliance can be successfully integrated into a mature yet strategically important antibiotic manufacturing platform.
From a chemistry perspective, the unique aminoglycoside structure of streptomycin provides potent antibacterial activity through irreversible inhibition of bacterial protein synthesis. The conversion of streptomycin into its sulfate salt form significantly enhances water solubility, stability, handling characteristics, and formulation flexibility, making it suitable for a wide range of pharmaceutical dosage forms.
From a manufacturing perspective, industrial production relies on carefully optimized fermentation processes utilizing selected strains of Streptomyces griseus. Continuous improvements in strain engineering, fermentation control strategies, nutrient feeding systems, oxygen transfer efficiency, and metabolic pathway optimization have substantially increased production titers compared with historical manufacturing processes. Modern facilities increasingly employ automation, digital process monitoring, and Process Analytical Technology (PAT) systems to ensure batch-to-batch consistency and maximize manufacturing efficiency.
Downstream processing remains one of the most critical determinants of product quality and overall production economics. The successful integration of filtration, ion-exchange purification, concentration, sulfation, crystallization, drying, and milling operations directly impacts product potency, impurity profiles, particle size distribution, and regulatory compliance. Advances in chromatography media, membrane separation technologies, and continuous purification systems are expected to further improve recovery yields while reducing operational costs.
The implementation of Quality by Design (QbD) principles and risk-based process development methodologies has transformed the manufacturing approach for Streptomycin Sulfate. Identification and control of Critical Quality Attributes (CQAs) and Critical Process Parameters (CPPs) enable manufacturers to establish highly robust production systems that consistently meet the requirements of global regulatory agencies. Compliance with current Good Manufacturing Practices (cGMP) and adherence to international pharmacopoeial standards such as USP, EP, and JP remain fundamental requirements for market access and long-term commercial success.
The Chemistry, Manufacturing, and Controls (CMC) framework provides the scientific foundation necessary for regulatory submissions, lifecycle management, and continuous process verification. Comprehensive characterization of raw materials, fermentation intermediates, process-related impurities, degradation products, and final API quality attributes ensures that manufacturers can maintain regulatory compliance while supporting future product development and market expansion initiatives.
Similarly, the Drug Master File (DMF) serves as a critical regulatory asset, providing detailed confidential information regarding manufacturing procedures, analytical methods, process validation, stability data, and quality control systems. A well-prepared DMF not only facilitates customer regulatory submissions but also demonstrates the technical capability and quality commitment of the API manufacturer.
From a commercial perspective, Streptomycin Sulfate continues to maintain a stable position within the global antibiotic market despite increasing competition from newer antimicrobial agents. Ongoing demand is supported by several key sectors:
- Tuberculosis treatment programs in selected regions.
- Veterinary pharmaceutical formulations.
- Laboratory and microbiological applications.
- Agricultural disease management programs.
- Research and diagnostic industries.
Global demand patterns indicate that Asia-Pacific remains the dominant manufacturing and consumption region due to its extensive fermentation infrastructure, favorable production economics, and strong pharmaceutical manufacturing base. Meanwhile, Europe and North America continue to represent important markets for high-quality pharmaceutical-grade material, particularly in specialized medical and research applications.
Economic analysis demonstrates that production competitiveness increasingly depends on achieving higher fermentation titers, improved downstream recovery yields, reduced energy consumption, and enhanced process integration. Manufacturers capable of achieving superior overall process yields can realize substantial reductions in cost per kilogram while simultaneously improving environmental sustainability and regulatory compliance.
Looking forward, several technological developments are expected to influence the future of Streptomycin Sulfate manufacturing:
Synthetic Biology
Advanced genome engineering technologies may enable the construction of next-generation production strains with significantly improved productivity, reduced by-product formation, and enhanced process robustness.
Precision Fermentation
Artificial intelligence, machine learning, and predictive modeling tools are increasingly being integrated into fermentation operations to optimize nutrient feeding, oxygen transfer, and process control in real time.
Continuous Bioprocessing
The transition from traditional batch processing toward continuous fermentation and continuous downstream purification may significantly improve productivity while reducing facility footprint and operating costs.
Green Manufacturing Technologies
Sustainability considerations are becoming increasingly important within the pharmaceutical industry. Future manufacturing facilities are expected to adopt energy-efficient equipment, wastewater recycling systems, carbon reduction initiatives, and environmentally responsible process designs.
Advanced Analytical Technologies
Modern analytical platforms such as high-resolution mass spectrometry, process analytical technologies, real-time release testing, and digital quality management systems will further strengthen product quality assurance and regulatory compliance capabilities.
Global Regulatory Harmonization
Efforts toward harmonization among regulatory authorities may simplify product registration processes, facilitate international trade, and reduce compliance complexity for manufacturers operating across multiple regions.
In conclusion, Streptomycin Sulfate (CAS No. 3810-74-0) remains a scientifically significant, commercially relevant, and technologically sophisticated fermentation-derived antibiotic. Its production combines advanced microbial biotechnology, chemical engineering, pharmaceutical manufacturing, and regulatory science into a highly integrated industrial process.
As the pharmaceutical industry continues to evolve toward greater efficiency, sustainability, digitalization, and quality excellence, Streptomycin Sulfate manufacturing is expected to benefit from ongoing innovations in synthetic biology, intelligent process control, continuous manufacturing, and green production technologies. These advancements will help ensure that this historically important antibiotic continues to serve global healthcare, veterinary medicine, agriculture, and scientific research for many years to come.
Appendix A: Typical Commercial Specifications for Pharmaceutical Grade Streptomycin Sulfate
| Test Item | Typical Specification |
| Appearance | White or almost white powder |
| Identification | Complies |
| Potency | ≥720 IU/mg (or pharmacopoeial requirement) |
| pH (1% solution) | 4.5 – 7.0 |
| Loss on Drying | ≤7.0% |
| Sulfate Content | Conforms |
| Related Substances | Complies |
| Heavy Metals | Complies |
| Microbial Limits | Complies |
| Residual Solvents | Complies ICH Q3C |
| Endotoxins | As required by application |
Appendix B: Typical Manufacturing Capacity Range
| Plant Scale | Annual Capacity |
| Small Commercial Facility | 10–50 MT |
| Medium Commercial Facility | 50–200 MT |
| Large Industrial Facility | 200–500+ MT |
Appendix C: Key Regulatory Guidelines Commonly Referenced
- ICH Q7: Good Manufacturing Practice for Active Pharmaceutical Ingredients
- ICH Q8: Pharmaceutical Development
- ICH Q9: Quality Risk Management
- ICH Q10: Pharmaceutical Quality System
- ICH Q11: Development and Manufacture of Drug Substances
- USP General Chapters
- European Pharmacopoeia Monographs
- Japanese Pharmacopoeia Standards
- FDA Guidance for Industry on API Manufacturing
- EMA Guidelines on Active Substance Manufacturing